DVA Risk Pregnancy

NCT ID: NCT02340442

Last Updated: 2015-09-01

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

120 participants

Study Classification

OBSERVATIONAL

Study Start Date

2013-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Maternal obesity, overweight and hypertensive disorders are among the most important risk factors for complications during pregnancy. Several lines of evidence indicate that overweight or obese women, as well as women with hypertensive disorders show increased risks of preterm birth before 32 weeks. However, an easy to determine, common reliable prognostic factor which allows for the early identifications of risk patients is still lacking. Recently, it has been reported that assessment of endothelial function may be a new promising tool for predicting the risk of adverse pregnancy outcome. As such evidence has been provided that endothelial dysfunction is prevalent among women with preeclampsia and is able to identify women at increased risk of preterm delivery and small-for-gestational-age (SGA) births. Several lines of evidence indicate that functional and structural changes of retinal vessels are altered in vascular related disease and may predict cardio-vascular events. Consequently, the current study seeks to investigate whether flicker induced vasodilatation, a well established parameter to test vascular function in-vivo is altered in women with low and high risk pregnancies when compared to a healthy control group. The data gained from this study may provide the basis for a larger longitudinal trial to assess whether vascular changes in the retina may predict the risk for complication during pregnancy.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pregnancy High Risk Pregnancies

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Low risk group

40 subjects: Healthy, pregnant women

Obstetrical care parameters

Intervention Type OTHER

DVA measurements

Intervention Type OTHER

Fundus photographs

Intervention Type OTHER

High risk group

40 pregnant women:

* 20 Pregnant women with preeclampsia
* 20 Obese pregnant women

Obstetrical care parameters

Intervention Type OTHER

DVA measurements

Intervention Type OTHER

Fundus photographs

Intervention Type OTHER

Healthy control subjects

40 subjects

Obstetrical care parameters

Intervention Type OTHER

DVA measurements

Intervention Type OTHER

Fundus photographs

Intervention Type OTHER

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Obstetrical care parameters

Intervention Type OTHER

DVA measurements

Intervention Type OTHER

Fundus photographs

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* • Age \>18 years

* Written informed consent
* Pregnancy at screening
* Normal ophthalmic findings, unless the investigator considers a finding clinically irrelevant.
* Ametropy \<= 3,5 Dpt.

For pregnant women with preeclampsia:

* Systolic BP ≥140 mmHg, or diastolic BP ≥90 mmHg on at least 2 occasions AND
* Proteinuria (≥300 mg/day) after 20 weeks of gestation in preeclampsia
* Pregnant at the time of confirming diagnosis of preeclampsia

For pregnant women with obesity:

• Pre-pregnancy BMI ≥30 as assessed from medical history

According to the WHO BMI classification:

* Underweight (less than 18.5)
* normal weight (18.5-24.9)
* overweight (25-29.9)
* obese class I (30 -34.9)
* obese class II (35-39.9)
* obese class III (40 or more) For non-pregnant control subjects

* Age \>18 years
* Written informed consent
* Not pregnant at screening
* Normal ophthalmic and medical findings, unless the investigator considers a finding clinically irrelevant.
* Ametropy \<= 3,5 Dpt.

Exclusion Criteria

* Diabetes mellitus type I or II
* Renal failure requiring dialysis
* Cirrhosis of liver
* Collagenosis
* Vasculitis
* Paraproteinaemia
* Alcohol abuse
* Amyloidosis
* Clinical signs of polyneuropathy
* Any other clinical finding, unless the clinical investigator considers a finding to be non clinically significant.
Minimum Eligible Age

18 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Medical University of Vienna

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Harald, Zeisler

Prof. Dr.

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Department of Clinical Pharmacology

Vienna, Vienna, Austria

Site Status RECRUITING

Department of Gynecology

Vienna, Vienna, Austria

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Austria

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Harald Zeisler, Prof. MD

Role: CONTACT

01/40400 - 2881

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Reinhard Told

Role: primary

01/40400/2988

Harald Zeisler, Prof. MD

Role: primary

01/40400 - 2881

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

OPHT-060513

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

HOME: Home Monitoring of High-risk Pregnancies
NCT05763069 ENROLLING_BY_INVITATION